1. Scrip
  2. >>Business
  3. >>Deals

Bursting Bacteria And Busting Resistance: AiCuris And Lysando’s New Partnership

 
• By Eleanor Malone

German anti-infectives firm AiCuris partners to develop new class of Artilysin antimicrobials that rapidly burst bacterial cells and could have an improved resistance profile.

explosion
Artilysins are designed to burst bacterial cells • Source: Shutterstock

The anti-infectives developer AiCuris Anti-infective Cures GmbH has signed a long-term co-operation agreement to develop and optimize a novel class of antibacterials from Liechtenstein-based Lysando and its German R&D group Lisando. The agreement gives AiCuris broad exclusive access to develop Lysando’s Artilysin technology across human infectious disease.

Artilysins are artificially modified versions of the lysin enzymes produced by bacteriophages at the end of their replication cycle to break down the peptidoglycan of the bacterial cell wall and release the viral progeny

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.